XSHE
300723
Market cap2.22bUSD
Oct 09, Last price
33.42CNY
1D
1.77%
1Q
-15.92%
IPO
234.20%
Name
ApicHope Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
ApicHope Pharmaceutical Co., Ltd, along with its various subsidiary entities, operates primarily in the pharmaceutical sector, focusing on the research, development, production, and distribution of medicinal products. The company boasts an extensive portfolio of offerings that address diverse therapeutic needs, including solutions for infectious diseases, pediatric health, cardiovascular conditions, genitourinary disorders, respiratory ailments, liver and digestive problems, and dermatological complaints. Furthermore, they supply a range of anti-inflammatory and pain-relieving medications. This enterprise, established in 2002, maintains its primary operations in Guangzhou, China. It adopted its current name, ApicHope Pharmaceutical Co., Ltd, in December 2021, having previously been known as Yipinhong Pharmaceutical Co.,Ltd.
Key people
Huixing Zhang
Chief Financial Officer · since 2021
Dongling Yang
Deputy General Manager · since 2025
Mingyuan Zhang
Deputy General Manager, Secretary of the Board · since 2024
Liangwen Huang
Staff Elected Director · since 2025
Handong Li
Director · since 2021
Hanxiong Li
Chairman of the Board, General Manager · since 2022
Xianhua Hu
Independent Director · since 2024
Kejian Zhang
Independent Director · since 2024
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||